Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals IncfiledCriticalSpectrum Pharmaceuticals Inc
Publication of AR123058A1publicationCriticalpatent/AR123058A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporciona un método para tratar NSCLC en un sujeto. El método generalmente incluye administrar una cantidad terapéuticamente eficaz de poziotinib o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite. El poziotinib exhibe eficacias mejoradas en sujetos con ciertas mutaciones del exón 20 de EGFR o HER2, que dan como resultado resistencia a los inhibidores de tirosina quinasa convencionales.A method of treating NSCLC in a subject is provided. The method generally includes administering a therapeutically effective amount of poziotinib or a pharmaceutically acceptable salt thereof to a subject in need thereof. Poziotinib exhibits enhanced efficacies in subjects with certain EGFR exon 20 or HER2 mutations, which result in resistance to conventional tyrosine kinase inhibitors.
ARP210102081A2020-07-272021-07-27
POZIOTINIB THERAPY FOR NON-SMALL CELL LUNG CANCER
AR123058A1
(en)
methods for controlling the dosage of an antitumor drug administered to a cancer patient, for administering at least one antitumor drug in two separate doses in a cancer patient and for selecting at least one antitumor drug